Patent application number | Description | Published |
20110306660 | LIQUID CANNABINOID FORMULATIONS - Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability. | 12-15-2011 |
20130296368 | SUBLINGUAL FENTANYL SPRAY - The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable sale thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations. | 11-07-2013 |
20130327321 | SUBLINGUAL FENTANYL SPRAY - The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable salt thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations. | 12-12-2013 |
20140100269 | ORAL CANNABINOID FORMULATIONS - Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability. | 04-10-2014 |
20140343100 | SUBLINGUAL FENTANYL SPRAY - The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable salt thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations. | 11-20-2014 |
20140343288 | SUBLINGUAL FENTANYL SPRAY - The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable sale thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations. | 11-20-2014 |
20150071971 | SUBLINGUAL BUPRENORPHINE SPRAY - The invention provides sublingual formulations containing buprenorphine, a pharmaceutically acceptable salt thereof, or a derivative thereof. The invention further provides sublingual formulations containing buprenorphine and naloxone, pharmaceutically acceptable salts thereof or derivatives thereof. The invention further provides a method of treating pain or opioid dependence by administering sublingual formulations containing buprenorphine, a pharmaceutically acceptable salt thereof, or a derivative thereof to a patient in need thereof. | 03-12-2015 |
20150133517 | ONDANSETRON SUBLINGUAL SPRAY FORMULATION - The invention is directed to sublingual spray formulations containing ondansetron or a pharmaceutically acceptable salt thereof and water. The invention is further directed to methods for treating or preventing nausea and emesis associated with cancer treatments by administering sublingual spray formulations containing ondansetron or a pharmaceutically acceptable salt thereof to a patient in need thereof. | 05-14-2015 |